Catheter Precision secures UK approval for LockeT; partners with distributor HC21

Catheter Precision, Inc.

LockeT suture retention device approved for commercialization in the UK; received CE Mark in May 2025.
Exclusive distribution agreement with HC21 (€180M revenue, 500+ employees across UK and Ireland).
LockeT aims to enhance patient comfort, enable earlier discharge, and help NHS reduce waiting lists.
Fatih Ayoglu (Sales Manager EMEA & APAC) highlighted potential to free up hospital capacity and accelerate patient throughput.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.